Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gilead SciencesFRA:GIS -0.75%74 EV-to-OCF is 15.53 as of Sep. 06, 2026, which is 40% above its 10-year median of 11.13. GuruFocus rates FRA:GIS with a GF Score™ of 74/100 and a GF Value™ of €90.13 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Gilead Sciences ranks worse than 62.26% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Gilead Sciences's Enterprise Value is €180,782 Mil.
Gilead Sciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was €11,643 Mil. Therefore, Gilead Sciences's EV-to-OCF for today is 15.53.
The historical rank and industry rank for Gilead Sciences's EV-to-OCF or its related term are showing as below:
FRA:GIS'
s EV-to-OCF Range Over the Past 10 Years
Min: 5.76 Med: 11.13 Max: 20.89
Current: 15.51
During the past 13 years, the highest EV-to-OCF of Gilead Sciences was 20.89. The lowest was 5.76. And the median was 11.13.
FRA:GIS's EV-to-OCF is ranked worse than 62.26% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 10.44
vs FRA:GIS: 15.51
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Gilead Sciences's PE Ratio (TTM) for today is calculated as:
Gilead Sciences's share price for today is €127.84.
Gilead Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.386.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Gilead Sciences EV-to-OCF Related Terms
Gilead Sciences EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Gilead Sciences's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Gilead Sciences's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gilead Sciences EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Gilead Sciences's EV-to-OCF falls into.
Gilead Sciences's current Enterprise Value is €180,782 Mil.
Gilead Sciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €11,643 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gilead Sciences (FRA:GIS) has a EV-to-OCF of 15.53 as of Sep. 06, 2026. This is 40% above median its historical median of 11.13. Over the past decade, Gilead Sciences' EV-to-OCF has ranged from 5.76 to 20.89. According to the industry distribution chart, Gilead Sciences ranks #627 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 62.3%.
Is Gilead Sciences' EV-to-OCF too high?
Gilead Sciences' current EV-to-OCF of 15.53 is 40% above median its 10-year median of 11.13. Over the past 10 years, this metric has ranged from a low of 5.76 to a high of 20.89. The Drug Manufacturers industry median EV-to-OCF is 10.44. Gilead Sciences' value of 15.53 is 48.8% above this industry median. Based on the distribution chart, Gilead Sciences ranks #627 out of 1007 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Gilead Sciences has a GF Score™ of 74/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gilead Sciences' EV-to-OCF compare to PFE and BMY?
According to the Drug Manufacturers industry distribution chart, Gilead Sciences ranks #627 out of 1007 companies for EV-to-OCF. This places Gilead Sciences in the lower half of its industry. The industry median EV-to-OCF is 10.44. Gilead Sciences' value of 15.53 is 48.8% above this benchmark. Historically, Gilead Sciences' own EV-to-OCF has ranged from 5.76 to 20.89 over the past decade. While the company's 10-year median is 11.13 vs. the industry median of 10.44, Gilead Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 10.44, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gilead Sciences's current EV-to-OCF of 15.53 is 48.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 10.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gilead Sciences's current EV-to-OCF is 15.53, which is 40% above median its own 10-year median of 11.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gilead Sciences stock overvalued right now?
Based on GuruFocus' analysis, Gilead Sciences (FRA:GIS) is currently considered Significantly Overvalued. The stock's GF Value™ is €90.13, compared to a current price of €127.84 — trading 41.8% above its estimated fair value. The current EV-to-OCF is 15.53, which is 40% above median its 10-year median of 11.13 and 48.8% above the Drug Manufacturers industry median of 10.44. Gilead Sciences' overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Gilead Sciences (FRA:GIS), the current EV-to-OCF is 15.53 as of Sep. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gilead Sciences (FRA:GIS) Overvalued in 2026?
Based on GuruFocus' analysis, Gilead Sciences stock appears to be overvalued.
The current stock price of €127.84 is trading 41.8% above its estimated GF Value™ of €90.13.
GuruFocus considers Gilead Sciences to be Significantly Overvalued.
Key valuation signals for FRA:GIS:
EV-to-OCF: 15.53 (40% above median its 10-year median of 11.13)
GF Value™: €90.13 vs. price of €127.84 (41.8% above fair value)
Industry Position: 48.8% above the Drug Manufacturers median (#627 of 1007)
No single metric tells the full story. See the FRA:GIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
74GF Score
Get the complete analysis for FRA:GIS
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:GIS has been successfully added to your 
